Skip to content
Head to head

Insmed vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: INSM · VRTX

Updated moments ago

1-year performance, rebased to 100

INSM -28.4%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
INSMVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price141.33515.02
Change today-2.17%-1.08%
1-year return-29.2%+22.0%
Market cap$31.01B$130.58B
52-week range90.39 – 212.75412.27 – 568.67
Valuation
P/E (TTM)-50.3033.14
P/E percentile, own 5-yr range0th99th
P/B42.706.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-6.4215.32
Net profit (TTM)$-1.41B$3.88B
Revenue (TTM)$1.52B$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+268.4%+11.8%
Gross margin84.4%85.5%
Operating margin-41.7%33.1%
Net margin-39.9%30.7%
Free cash flow (TTM)$-627.58M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership101.8%96.8%
Insider activity (12mo)11 buy / 37 sell28 buy / 22 sell
Short interest (% of float)6.4%1.9%
Analyst consensus94% buy / 6% hold (16)95% buy / 5% hold (21)
Analyst price target$191 (+35%)$624 (+21%)
StockVane view
StockVane Quant RatingD (14)C (68)
Company
Employees1,6646,400
Founded19881989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.